HOME >> MEDICINE >> NEWS
Commonly recommended sedative does not improve infant sleep

An antihistamine often recommended to parents whose infants do not sleep through the night may not be effective in reducing nighttime awakenings or improving parents' happiness with their children's sleep, according to a report in the July issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

Between 20 and 46 percent of parents have reported that their infants have trouble sleeping, according to background information in the article. Some parents let their children cry for extended periods at night--this method, known as crying out, is popular but controversial among parents and health care professionals. Another commonly used method is to give children medications--such as antihistamines, normally used to treat allergies--to sedate them at bedtime. Diphenhydramine hydrochloride, sold as Benadryl, is often used by parents and recommended by physicians despite the fact that it has not been studied in children younger than age 2 years.

Dan Merenstein, M.D., then at The Johns Hopkins School of Medicine, Baltimore, and now at Georgetown University, Washington, D.C., and colleagues conducted a trial of diphenhydramine in 44 children ages 6 to 15 months who slept in cribs. Parents in the study had all reported that their children woke up two or more times per night. The participating infants were randomly assigned to receive 100 mL of diphenhydramine or placebo (inactive medication) in a cherry-flavored liquid 30 minutes before bedtime for one week between May 2004 and May 2005. Parents reported whether the child had fewer awakenings that required parental intervention during that week and also tracked their child's sleep in a diary for the first 28 days. At four points during the first 43 days of the study, parents were asked to rate their happiness with their children's sleep on a scale of one to 10.

Three of 22 participants in the placebo group and one of 22 participants in the dip
'"/>

Contact: Liz McDonald
202-687-5100
JAMA and Archives Journals
3-Jul-2006


Page: 1 2

Related medicine news :

1. Commonly used drug offers promise for premature babies
2. Commonly used pain medications do not prevent Alzheimers disease
3. Commonly used blood pressure medication prevents aortic aneurysm in mice with Marfan syndrome
4. Commonly used drug may prevent fetal alcohol syndrome
5. Commonly used antidepressants may also affect human immune system
6. Should adult male circumcision be recommended for HIV prevention in the US?
7. Medicaid patients less likely than those with private insurance to receive recommended cardiac care
8. Updated sleep apnea screening recommended for commercial drivers
9. Study provides evidence supporting recommended 10 year interval for colonoscopies for most patients
10. Many breast cancer survivors not getting recommended mammograms
11. Older patients with acute coronary syndromes not getting recommended treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Commonly recommended sedative does not improve infant sleep

(Date:8/20/2014)... 20, 2014 BCC Research ( ... PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS ... is expected to grow to $15.2 billion by ... (CAGR) of 15.9%. Increasing industrialization is driving ... a rapidly expanding range of industrial applications such ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... (HealthDay News) -- Leaving the car at home and getting ... for your health, a new study indicates. Researchers looked ... that 76 percent of men and 72 percent of women ... of women used public transit, and 14 percent of men ... who drove to work weighed more and had higher levels ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... leading nonprofit authority on the use of health ... announced the full agenda for its annual fall ... IT Efficiency. WEDI-Con 2014 will take place at ... 20-23, 2014, attracting a diverse cross-section of payers, ...
(Date:8/20/2014)... Parents and kids across the nation are ... means buying textbooks and arranging after school care, there ... part of the annual re-commitment to your child’s education; ... Association, 27% of students say they experience "extreme stress" ... are stressed by school pressures. The study, Stress in ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
Cached News: